Wirth M, Fuchs A, Wolf M, Ertl B, Gabor F
Institute of Pharmaceutical Technology, the University of Vienna, Austria.
Pharm Res. 1998 Jul;15(7):1031-7. doi: 10.1023/a:1011926026653.
To investigate the usefulness of wheat germ agglutinin as a targeting carrier protein for an acid-labile chemotherapeutic prodrug directed against colon carcinoma cells in vitro.
Cis-aconityl-linked doxorubicin-wheat germ agglutinin was prepared by a two step procedure and the conjugate-binding capacity of target- and non-target cells was assayed by flow cytometry. The antiproliferative activity of the prodrug on Caco-2 and MOLT-4 cells was determined by the XTT- and BrdU-test and compared with that of the parent drug and the lectin alone.
At pH 4.0, about 50% of the conjugated doxorubicin were released within 24 h from the water soluble prodrug exhibiting a conjugation number of 24 (mol doxorubicin/mol WGA). The prodrug-binding capacity of colon carcinoma cells exceeded that of human colonocytes and lymphoblastic MOLT-4 cells 4.5-fold. Additionally, the antiproliferative effect of the conjugate on Caco-2 cells was 39% as opposed to 5% in case of MOLT-4 cells. As the unmodified carrier protein inhibited or stimulated Caco-2 cell growth in a concentration-dependent manner, the cytostatic activity of the conjugate was determined at WGA concentrations without an effect on cell-proliferation. Considering 50% release of conjugated drug at the most, the prodrug yielded 160% of the cytostatic activity of free doxorubicin.
WGA-prodrug targeting offers new perspectives for site-specific, cytoinvading drug delivery in colon cancer chemotherapy.
研究麦胚凝集素作为一种靶向载体蛋白,用于体外针对结肠癌细胞的酸不稳定化疗前体药物的效用。
通过两步法制备顺乌头酰连接的阿霉素 - 麦胚凝集素,并通过流式细胞术检测靶细胞和非靶细胞的共轭结合能力。通过XTT和BrdU试验测定前体药物对Caco - 2和MOLT - 4细胞的抗增殖活性,并与母体药物和单独的凝集素进行比较。
在pH 4.0时,约50%的共轭阿霉素在24小时内从水溶性前体药物中释放出来,其共轭数为24(阿霉素摩尔数/麦胚凝集素摩尔数)。结肠癌细胞的前体药物结合能力超过人结肠细胞和淋巴细胞性MOLT - 4细胞4.5倍。此外,共轭物对Caco - 2细胞的抗增殖作用为39%,而对MOLT - 4细胞为5%。由于未修饰的载体蛋白以浓度依赖的方式抑制或刺激Caco - 2细胞生长,因此在对细胞增殖无影响的麦胚凝集素浓度下测定共轭物的细胞抑制活性。考虑到共轭药物最多释放50%,前体药物产生的细胞抑制活性是游离阿霉素的160%。
麦胚凝集素 - 前体药物靶向为结肠癌化疗中位点特异性、细胞侵袭性药物递送提供了新的前景。